secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Pharma, Inc. (BBIO)
CIK:        0001743881
Form:       8-K
Filed at:   2026-01-21T23:59:59+00:00
Accession:  0001140361-26-001843
Event type: debt
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 2.03, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BridgeBio issues $632.5M of 0.75% convertible notes due 2033, prefunds repayment of 2027 notes
--------------------------------------------------------------------------------

- Aggregate $632.5M principal (incl. $82.5M initial purchasers' option), 0.75% coupon, due Feb 1, 2033.
- Net proceeds ~$619.3M; intended to repurchase, settle, or repay at maturity the 2.50% 2027 notes.
- Concurrent $82.5M share repurchase: 1,081,825 shares at $76.26/share from note purchasers.
- Initial conversion price ~$110.58/share, a ~45% premium over Jan 15 close of $76.26.
- Notes are senior unsecured; redemption permitted after Feb 6, 2030 if stock >=130% of conversion price.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1743881/000114036126001843/0001140361-26-001843-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1743881/000114036126001843/ef20063486_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-001843

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer